Advertisement

Inflammation

, Volume 41, Issue 5, pp 1974–1986 | Cite as

Novel Anti-arthritic Mechanisms of Polydatin in Complete Freund’s Adjuvant-Induced Arthritis in Rats: Involvement of IL-6, STAT-3, IL-17, and NF-кB

  • Kamel M. Kamel
  • Amany M. Gad
  • Suzan M. Mansour
  • Marwa M. Safar
  • Hala M. Fawzy
ORIGINAL ARTICLE
  • 103 Downloads

Abstract

Articular manifestations are the main hall mark for rheumatoid arthritis; inflammation and oxidative stress are involved in its pathogenesis. This study was designed to figure out the possible therapeutic potential of polydatin on experimentally induced arthritis in rats. Polydatin (POLY) was administered (200 mg/kg, p.o.) for 21 days to complete Freund’s adjuvant (CFA; 0.1 ml, s.c.)-induced arthritic rats. Meanwhile, methotrexate (MTX; 0.75 mg/kg, i.p.) was given as a reference standard disease-modifying anti-rheumatic drug (DMARD). Both POLY and MTX significantly attenuated articular damage associated with CFA-induced arthritis. This was manifested by reducing levels of tumor necrosis factor alpha (TNF-α), interleukin-6 (IL-6), interleukin-17 (IL-17), and matrix metalloproteinase-3 (MMP-3), paralleled with marked decrease in hind paw and ankle diameters. Moreover, POLY and MTX downregulated gene expressions of receptor activator of nuclear factor kappa-B ligand (RANKL) as well as signal transducer and activator of transcription-3 (STAT3) besides hampering immunohistochemical staining of vascular endothelial growth factor (VEGF) and nuclear factor kappa-B (NF-κB). Furthermore, substantial decline in myeloperoxidase (MPO) activity and malondialdehyde (MDA) level associated with significant rise in reduced glutathione content (GSH) was observed. These findings provide an innovative therapeutic approach of POLY as a natural anti-arthritic drug through modulating IL-6/STAT-3/IL-17/NF-кB cascade.

Graphical Abstract

KEY WORDS

polydatin methotrexate cytokines synovitis pannus 

Notes

Compliance and Ethical Standards

Conflict of Interest

The authors declare that they have no conflict of interest.

Ethical Approval

All procedures performed in studies involving animals were in accordance with the ethical standards of the institution or practice at which the studies were conducted.

References

  1. 1.
    Frank-bertoncelj, Mojca. 2017. Interplay between genetic and epigenetic mechanisms in rheumatoid arthritis. Epigenomics 9: 493–504.CrossRefPubMedGoogle Scholar
  2. 2.
    Choy, E. 2012. Understanding the dynamics: Pathways involved in the pathogenesis of rheumatoid arthritis. Rheumatology (Oxford) 51 (Suppl 5): v3–v11.  https://doi.org/10.1093/rheumatology/kes113.CrossRefGoogle Scholar
  3. 3.
    McInnes, I.A. 2011. The pathogenesis of rheumatoid arthritis. The New England Journal of Medicine 365: 2205–2219.CrossRefPubMedGoogle Scholar
  4. 4.
    Arab, Hany H., and Maha M. El-sawalhi. 2013. Carvedilol alleviates adjuvant-induced arthritis and subcutaneous air pouch edema: Modulation of oxidative stress and inflammatory mediators. Toxicology and Applied Pharmacology 268. Elsevier Inc.: 241–248.  https://doi.org/10.1016/j.taap.2013.01.019.CrossRefPubMedGoogle Scholar
  5. 5.
    Huhtakangas, Johanna A., Johanna Veijola, Sanna Turunen, Anna Karjalainen, Maarit Valkealahti, Tomi Nousiainen, Susanna Yli-luukko, Olli Vuolteenaho, and Petri Lehenkari. 2017. 1,25(OH) 2 D 3 and calcipotriol, its hypocalcemic analog, exert a long-lasting anti-inflammatory and anti-proliferative effect in synoviocytes cultured from patients with rheumatoid arthritis and osteoarthritis. Journal of Steroid Biochemistry and Molecular Biology 25. Elsevier Ltd: 1–35.  https://doi.org/10.1016/j.jsbmb.2017.01.017.Google Scholar
  6. 6.
    Komatsu, Noriko, and Hiroshi Takayanagi. 2012. Inflammation and bone destruction in arthritis: Synergistic activity of immune and mesenchymal cells in joints. Frontiers in Immunology 3: 1–11.  https://doi.org/10.3389/fimmu.2012.00077.CrossRefGoogle Scholar
  7. 7.
    Chen, Xiao Wu, and Shu Feng Zhou. 2015. Inflammation, cytokines, the IL-17/IL-6/STAT3/NF-κB axis, and tumorigenesis. Drug Design, Development and Therapy 9: 2941–2946.  https://doi.org/10.2147/DDDT.S86396.PubMedPubMedCentralGoogle Scholar
  8. 8.
    Iwakura, Yoichiro, Harumichi Ishigame, Shinobu Saijo, and Susumu Nakae. 2011. Functional specialization of interleukin-17 family members. Immunity 34. Elsevier Inc.: 149–162.  https://doi.org/10.1016/j.immuni.2011.02.012.CrossRefPubMedGoogle Scholar
  9. 9.
    Tomita, Tetsuya, Eiji Takeuchi, Naruya Tomita, Ryuichi Morishita, Motoharu Kaneko, K.E.I. Yamamoto, Takanobu Nakase, et al. 1999. Suppressed severity of collagen-induced arthritis by in vivo transfection of nuclear factor κB decoy oligodeoxynucleotides as a gene therapy. Arthritis and Rheumatism 42: 2532–2542.CrossRefPubMedGoogle Scholar
  10. 10.
    Huppert, Jula, Dorothea Closhen, Andrew Croxford, Robin White, Paulina Kulig, Eweline Pietrowski, Ingo Bechmann, et al. 2010. Cellular mechanisms of IL-17-induced blood-brain barrier disruption. The FASEB Journal 24: 1023–1034.  https://doi.org/10.1096/fj.09-141978.CrossRefPubMedGoogle Scholar
  11. 11.
    Murata, M.M.D., K.M.D. Yudoh, and K.M.D. Masuko. 2008. The potential role of vascular endothelial growth factor ( VEGF ) in cartilage how the angiogenic factor could be involved in the pathogenesis of osteoarthritis? Osteoarthritis and Cartilage 16: 279–286.  https://doi.org/10.1016/j.joca.2007.09.003. CrossRefPubMedGoogle Scholar
  12. 12.
    Zhu, L., W. Wei, Y. Zheng, and X. Jia. 2005. Effects and mechanisms of total glucosides of paeony on joint damage in rat collagen-induced arthritis. Inflammation Research 54: 211–220.  https://doi.org/10.1007/s00011-005-1345-x.CrossRefPubMedGoogle Scholar
  13. 13.
    Burrage, Peter S., Kimberlee S. Mix, and Constance E. Brinckerhoff. 2006. Matrix metalloproteinases: Role in arthritis. Frontiers in Bioscience: A Journal and Virtual Library 11: 529–543.  https://doi.org/10.2741/1817.CrossRefGoogle Scholar
  14. 14.
    McInnes, Iain B., and Georg Schett. 2007. Cytokines in the pathogenesis of rheumatoid arthritis. Nature Reviews. Immunology 7: 429–442.  https://doi.org/10.1038/nri2094.CrossRefPubMedGoogle Scholar
  15. 15.
    Wijnands, M.J.H., M.A. Van’t Hof, M.A. Van Leeuwen, M.H. Van Rijswijk, L.B.A. de Putte, and P.L.C.M. Van Riel. 1992. Long-term second-line treatment: A prospective drug survival study. Rheumatology 31. Oxford University Press: 253–258.CrossRefGoogle Scholar
  16. 16.
    Grove, M.L., A.B. Hassell, E.M. Hay, and M.F. Shadforth. 2001. Adverse reactions to disease-modifying anti-rheumatic drugs in clinical practice. QJM 94. Oxford University Press: 309–319.CrossRefPubMedGoogle Scholar
  17. 17.
    Chen, Lvyi, Zhou Lan, Qinxiong Lin, Xue Mi, Yingying He, Liuhong Wei, Yuanyuan Lin, Yu Zhang, and Xukun Deng. 2013. Polydatin ameliorates renal injury by attenuating oxidative stress-related inflammatory responses in fructose-induced urate nephropathic mice. Food and Chemical Toxicology 52. Elsevier: 28–35.CrossRefPubMedGoogle Scholar
  18. 18.
    Yuan, Meichun, Jianjie Li, Jingzhang Lv, Xucheng Mo, Chengbin Yang, Xiangdong Chen, Zhigang Liu, and Jie Liu. 2012. Polydatin (PD) inhibits IgE-mediated passive cutaneous anaphylaxis in mice by stabilizing mast cells through modulating Ca 2+ mobilization. Toxicology and Applied Pharmacology 264. Elsevier: 462–469.CrossRefPubMedGoogle Scholar
  19. 19.
    Lanzilli, Giulia, Andrea Cottarelli, Giuseppe Nicotera, Serena Guida, Giampiero Ravagnan, and Maria Pia Fuggetta. 2012. Anti-inflammatory effect of resveratrol and polydatin by in vitro IL-17 modulation. Inflammation 35: 240–248.  https://doi.org/10.1007/s10753-011-9310-z.CrossRefPubMedGoogle Scholar
  20. 20.
    Liu, H.B., Q.H. Meng, J.B. Huang, C. Wang, and X.W. Liu. 2015. Nephroprotective effects of polydatin against ischemia / reperfusion injury: A role for the PI3K / Akt signal pathway. Oxidative Medicine and Cellular Longevity 2015: 1–13.  https://doi.org/10.1155/2015/362158.Google Scholar
  21. 21.
    Jiang, Qi, Min Yi, Qianqian Guo, Ciman Wang, Huimin Wang, Shanshan Meng, Chao Liu, Fu Yeliu, Hui Ji, and Tong Chen. 2015. Protective effects of polydatin on lipopolysaccharide-induced acute lung injury through TLR4-MyD88-NF-кB pathway. International Immunopharmacology 29. Elsevier B.V.: 370–376.  https://doi.org/10.1016/j.intimp.2015.10.027.CrossRefPubMedGoogle Scholar
  22. 22.
    Darwish, Samar F., Wesam M. El-Bakly, Hossam M. Arafa, and Ebtehal El-Demerdash. 2013. Targeting TNF-α and NF-κB activation by bee venom: Role in suppressing adjuvant induced arthritis and methotrexate hepatotoxicity in rats. PLoS One 8: 1–13.  https://doi.org/10.1371/journal.pone.0079284.Google Scholar
  23. 23.
    Clark, J. Derrell, Gerald F. Gebhart, Janet C. Gonder, Michale E. Keeling, and Dennis F. Kohn. 1997. The 1996 guide for the care and use of laboratory animals. ILAR Journal 38. Institute for Laboratory Animal Research: 41–48.CrossRefPubMedGoogle Scholar
  24. 24.
    Izzo, Giuseppe Maria, and Giovanni Suffritti. 2017. Polydatin and atopic dermatitis in adults: Clinical study. Journal of Cosmetology and Trichology 3: 6.Google Scholar
  25. 25.
    Ji, Hui, Xiangjian Zhang, Yuanyuan Du, Haichao Liu, Shuya Li, and Litao Li. 2012. Polydatin modulates inflammation by decreasing NF-κB activation and oxidative stress by increasing Gli1, Ptch1, SOD1 expression and ameliorates blood-brain barrier permeability for its neuroprotective effect in pMCAO rat brain. Brain Research Bulletin 87. Elsevier: 50–59.CrossRefPubMedGoogle Scholar
  26. 26.
    Zhang, Hong, Yu Cheng-Hao, Yi-Ping Jiang, Cheng Peng, Kun He, Jian-Yuan Tang, and Hai-Liang Xin. 2012. Protective effects of polydatin from Polygonum cuspidatum against carbon tetrachloride-induced liver injury in mice. PLoS One 7. Public Library of Science: 1–10.Google Scholar
  27. 27.
    Wlodarski, K.H., and G.R. Dickson. 2002. Evaluation of locally induced osteoarthritis by the complete and incomplete Freund’s adjuvant in mice. The application of DEXA measurements. Folia Biologica-Praha 48. Institute of Molecular Genetics of the Czechoslovak: 192–199.Google Scholar
  28. 28.
    Wang, Hui Lin, Jian Ping Gao, Yu Liang Han, Xu Xu, Wu Rong, Yan Gao, and Xiao Hua Cui. 2015. Comparative studies of polydatin and resveratrol on mutual transformation and antioxidative effect in vivo. Phytomedicine 22: 553–559.  https://doi.org/10.1016/j.phymed.2015.03.014.CrossRefPubMedGoogle Scholar
  29. 29.
    Xu, Lie-Qiang, You-Liang Xie, Shu-Hua Gui, Xie Zhang, Zhi-Zhun Mo, Chao-Yue Sun, Cai-Lan Li, et al. 2016. Polydatin attenuates d-galactose-induced liver and brain damage through its anti-oxidative, anti-inflammatory and anti-apoptotic effects in mice. Food & Function 7. Royal Society of Chemistry: 4545–4555.CrossRefGoogle Scholar
  30. 30.
    Ince, S., F. Avdatek, H.H. Demirel, D. Arslan-Acaroz, E. Goksel, and I. Kucukkurt. 2016. Ameliorative effect of polydatin on oxidative stress-mediated testicular damage by chronic arsenic exposure in rats. Andrologia 48. Wiley Online Library: 518–524.CrossRefPubMedGoogle Scholar
  31. 31.
    Pfaffl, M.W. 2001. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Research 29: 2002–2007.  https://doi.org/10.1093/nar/29.9.e45.CrossRefGoogle Scholar
  32. 32.
    Tian, Zhen, Dong-sheng Wang, Xin-shang Wang, Jiao Tian, Jing Han, Yan-yan Guo, Bin Feng, Nan Zhang, Ming-gao Zhao, and Shui-bing Liu. 2015. Analgesic effects of NB001 on mouse models of arthralgia. Molecular Brain 8: 1–10.  https://doi.org/10.1186/s13041-015-0151-9.CrossRefGoogle Scholar
  33. 33.
    Banchroft, J.D., Stevans A., Turnes D.R. 1996. Theory and practice of histological techniques 4th ed., Livingstone. Edinburgh, London, Melbourne, New York, Tokyo.Google Scholar
  34. 34.
    Shahid, Muhammad, and Fazal Subhan. 2014. Comparative histopathology of acetaminophen induced hepatotoxicity in animal models of mice and rats. Pharmacologyonline 3: 32–43.Google Scholar
  35. 35.
    Ishihara, Katsuhiko, and Toshio Hirano. 2002. IL-6 in autoimmune disease and chronic inflammatory proliferative disease. Cytokine & Growth Factor Reviews 13: 357–368.CrossRefGoogle Scholar
  36. 36.
    Fishman, Daniel, Gary Faulds, Rachel Jeffery, Vidya Mohamed-ali, John S. Yudkin, Steve Humphries, and Patricia Woo. 1998. The effect of novel polymorphisms in the interleukin-6 ( IL-6 ) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. Journal of Clinical Investigation 102: 1369–1376.CrossRefPubMedPubMedCentralGoogle Scholar
  37. 37.
    Georganas, Constantinos, Hongtao Liu, Harris Perlman, Alexander Hoffmann, Bayar Thimmapaya, and M. Richard. 2000. Regulation of IL-6 and IL-8 expression in rheumatoid arthritis synovial fibroblasts: The dominant role for NF-κB but not C/EBP β or c-Jun. The Journal of Immunology 165: 7199–7206.  https://doi.org/10.4049/jimmunol.165.12.7199.CrossRefPubMedGoogle Scholar
  38. 38.
    Ravagnan, Giampietro, Anna De Filippis, Maria Cartenì, Salvatore De Maria, Valentina Cozza, Marcella Petrazzuolo, Maria Antonietta Tufano, and Giovanna Donnarumma. 2013. Polydatin, a natural precursor of resveratrol, induces β-defensin production and reduces inflammatory response. Inflammation 36: 26–34.  https://doi.org/10.1007/s10753-012-9516-8.CrossRefPubMedGoogle Scholar
  39. 39.
    Bang, Jun Soo, Oh. Da Hee, Hyun Mi Choi, Bong-jun Sur, Sung-jig Lim, Jung Yeon Kim, Hyung-in Yang, Myung Chul Yoo, Dae-hyun Hahm, and Kyoung Soo Kim. 2009. Anti-inflammatory and antiarthritic effects of piperine in human interleukin 1β-stimulated fibroblast-like synoviocytes and in rat arthritis models. Arthritis Research & Therapy 11: 1–9.  https://doi.org/10.1186/ar2662.CrossRefGoogle Scholar
  40. 40.
    Krause, Anja, Nicholas Scaletta, Jong-dae Ji, and B. Lionel. 2014. Rheumatoid arthritis synoviocyte survival is dependent on Stat3. The Journal of Immunology 169: 6610–6616.  https://doi.org/10.4049/jimmunol.169.11.6610.CrossRefGoogle Scholar
  41. 41.
    Zhou, Liang, Ivaylo I. Ivanov, Rosanne Spolski, Roy Min, Kevin Shenderov, Takeshi Egawa, David E. Levy, Warren J. Leonard, and Dan R. Littman. 2007. IL-6 programs TH-17 cell differentiation by promoting sequential engagement of the IL-21 and IL-23 pathways. Nature Immunology 8: 967–974.  https://doi.org/10.1038/ni1488.CrossRefPubMedGoogle Scholar
  42. 42.
    Jhun, Joo-yeon, Seong-beom Heo, Hyun-tak Jin, So-youn Min, Ji-hyeon Ju, Kyung-su Park, Chong-hyeon Yoon, et al. 2006. STAT3 and NF-κB signal pathway is required for IL-23-mediated IL-17 production in spontaneous arthritis animal model IL-1 receptor antagonist-deficient mice. The Journal of Immunology 176: 5652–5661.  https://doi.org/10.4049/jimmunol.176.9.5652.CrossRefPubMedGoogle Scholar
  43. 43.
    Lubberts, Erik, Marije I. Koenders, Birgitte Oppers-walgreen, Liduine Van Den Bersselaar, Christina J.J. Coenen-de Roo, Leo A.B. Joosten, and Wim B. Van Den Berg. 2004. Treatment with a neutralizing anti-murine interleukin-17 antibody after the onset of collagen-induced arthritis reduces joint inflammation, cartilage destruction, and bone erosion. Arthritis & Rheumatology 50: 650–659.  https://doi.org/10.1002/art.20001.CrossRefGoogle Scholar
  44. 44.
    Nakae, Susumu, Aya Nambu, Katsuko Sudo, and Email Alerts. 2003. Suppression of immune induction of collagen-induced arthritis in IL-17-deficient mice. The Journal of Immunology 171: 6173–6177.  https://doi.org/10.4049/jimmunol.171.11.6173.CrossRefPubMedGoogle Scholar
  45. 45.
    Yamamoto, Yumi, and Richard B. Gaynor. 2001. Role of the NF-κB pathway in the pathogenesis of human disease states. Current Molecular Medicine 1: 287–296.CrossRefPubMedGoogle Scholar
  46. 46.
    Tak, Paul P., and Gary S. Firestein. 2001. NF-κB in defense and disease NF-κB: A key role in inflammatory diseases. Journal of Clinical Investigation 107: 7–11.CrossRefPubMedPubMedCentralGoogle Scholar
  47. 47.
    Brennan, Fionula M., and Iain B. Mcinnes. 2008. Evidence that cytokines play a role in rheumatoid arthritis. The Journal of Clinical Investigation 118: 3537–3545.  https://doi.org/10.1172/JCI36389.in.CrossRefPubMedPubMedCentralGoogle Scholar
  48. 48.
    Zhang, Jingming, Yingying Tan, Fanrong Yao, and Q.I. Zhang. 2012. Polydatin alleviates non-alcoholic fatty liver disease in rats by inhibiting the expression of TNF- α and SREBP-1c. Molecular Medecine Reports 6: 815–820.  https://doi.org/10.3892/mmr.2012.1015.CrossRefGoogle Scholar
  49. 49.
    Paleolog, Ewa M., Sylvia Young, Alison C. Stark, Richard V. Mccloskey, Marc Feldma, and Ravinder N. Maini. 1998. Modulation of angiogenic vascular endothelial growth factor by tumor necrosis factor α and interleukin-1 in rheumatoid arthritis. Arthritis and Rheumatism 41: 1258–1265.CrossRefPubMedGoogle Scholar
  50. 50.
    Gtogenesis, A.N. 1998. Angiogenesis: Implications for rheumatoid arthritis. Arthritis and Rheumatism 41: 951–962.CrossRefGoogle Scholar
  51. 51.
    Paleolog, E.M. 1996. Angiogenesis: A critical process in the pathogenesis of RA-A role for VEGF? British Journal of Rheumatology 35: 917–920.CrossRefPubMedGoogle Scholar
  52. 52.
    Paleolog, Ewa M., and Jadwiga M. Miotla. 1999. Angiogenesis in arthritis: Role in disease pathogenesis and as a potential therapeutic target. Angiogenesis 2: 295–307.CrossRefGoogle Scholar
  53. 53.
    Hogg, Simon J., Kenny Chitcholtan, Wafaa Hassan, Peter H. Sykes, and Ashley Garrill. 2015. Resveratrol, acetyl-resveratrol, and polydatin exhibit antigrowth activity against 3D cell aggregates of the SKOV-3 and OVCAR-8 ovarian cancer cell lines. Obstetrics and Gynecology International 2015: 1–14.CrossRefGoogle Scholar
  54. 54.
    Cleland, Leslie, Lisa K. Stamp, Michael J. James, and Leslie G. Cleland. 2004. Interleukin-17: The missing link between T-cell accumulation and effector cell actions in rheumatoid arthritis ? Immunology and Cell Biology 82 (1): 1–9.  https://doi.org/10.1111/j.1440-1711.2004.01212.x.CrossRefPubMedGoogle Scholar
  55. 55.
    Li, Bo, and Xiao-Li Wang. 2016. Effective treatment of polydatin weakens the symptoms of collagen-induced arthritis in mice through its anti-oxidative and anti-inflammatory effects and the activation of MMP-9. Molecular Medicine Reports 14. Spandidos Publications: 5357–5362.CrossRefPubMedGoogle Scholar
  56. 56.
    Mapp, P.I., M.C. Grootveld, and D.R. Blake. 1995. Hypoxia, oxidative stress and rheumatoid arthritis. British Medical Bulletin 51: 419–436.CrossRefPubMedGoogle Scholar
  57. 57.
    Griffiths, Helen R. 2005. Review ROS as signalling molecules in T cells—Evidence for abnormal redox signalling in the autoimmune disease, rheumatoid arthritis. Redox Report 10: 273–280.  https://doi.org/10.1179/135100005X83680. CrossRefPubMedGoogle Scholar
  58. 58.
    Filippin, L.I., and R. Vercelino. 2008. Redox signalling and the inflammatory response in rheumatoid arthritis. Clinical and Experimental Immunology 152: 415–422.  https://doi.org/10.1111/j.1365-2249.2008.03634.x.CrossRefPubMedPubMedCentralGoogle Scholar
  59. 59.
    Hitchon, Carol A., and Hani S. El-gabalawy. 2004. Oxidation in rheumatoid arthritis. Arthritis Research & Therapy 6: 265–278.  https://doi.org/10.1186/ar1447.CrossRefGoogle Scholar
  60. 60.
    Odobasic, Dragana, A. Richard Kitching, and Stephen R. Holdsworth. 2016. Neutrophil-mediated regulation of innate and adaptive immunity: The role of myeloperoxidase Immunity. Journal of Immunology Research 2016. Hindawi Publishing Corporation: 1–11.  https://doi.org/10.1155/2016/2349817.CrossRefGoogle Scholar
  61. 61.
    El-sahar, Ayman E., Marwa M. Safar, Hala F. Zaki, Amina S. Attia, and Afaf A. Ain-shoka. 2015. Sitagliptin attenuates transient cerebral ischemia/reperfusion injury in diabetic rats: Implication of the oxidative–inflammatory–apoptotic pathway. Life Sciences 126: 81–86.CrossRefPubMedGoogle Scholar
  62. 62.
    Fabris, Sabrina, Federico Momo, Giampietro Ravagnan, and Roberto Stevanato. 2008. Biophysical chemistry antioxidant properties of resveratrol and piceid on lipid peroxidation in micelles and monolamellar liposomes. Biophysical Chemistry 135: 76–83.  https://doi.org/10.1016/j.bpc.2008.03.005. CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Pharmacology DepartmentNational Organization for Drug Control and ResearchGizaEgypt
  2. 2.Pharmacology & Toxicology Department, Faculty of PharmacyCairo UniversityCairoEgypt
  3. 3.Pharmacology, Toxicology & Biochemistry Department, Faculty of Pharmaceutical Sciences and Pharmaceutical IndustriesFuture University in EgyptNew CairoEgypt
  4. 4.Pharmacology & Biochemistry Department, Faculty of PharmacyThe British University in EgyptEl Sherouk CityEgypt

Personalised recommendations